Guangdong Hypnuse Biotechnology Co., Ltd – Trademark Portfolio
Entity Type: 99
Guangdong Hypnuse Biotechnology Co., Ltd has 3 U.S. trademark filings recorded with the United States Patent and Trademark Office (USPTO). Of these, 2 are successfully registered — a 67% registration rate. The portfolio includes marks such as HYPNUSE. Filings span 3 Nice Classification classes, with the highest activity in Class 25 (Clothing) and Class 9 (Computers & Electronics). This trademark owner is based in Dongguan, Guangdong.
Wusha Zhenyuan Road, Chang'an Town,
Room 103, Building 2, No. 6,West Street,
Dongguan, Guangdong 523000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Guangdong Hypnuse Biotechnology Co., Ltd's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Guangdong Hypnuse Biotechnology Co., Ltd have?
Guangdong Hypnuse Biotechnology Co., Ltd has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.
What trademark classes does Guangdong Hypnuse Biotechnology Co., Ltd file in?
Guangdong Hypnuse Biotechnology Co., Ltd files trademarks across 3 Nice Classification classes. The most active classes are Class 25 (Clothing), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). Class 25 covers clothing, footwear, headgear.
What are Guangdong Hypnuse Biotechnology Co., Ltd's most well-known trademarks?
Guangdong Hypnuse Biotechnology Co., Ltd's registered trademark portfolio includes well-known marks such as HYPNUSE. These are among 2 currently registered trademarks in the portfolio.
What is Guangdong Hypnuse Biotechnology Co., Ltd's trademark registration success rate?
Guangdong Hypnuse Biotechnology Co., Ltd has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.